representing a drug reaction, although an intrinsic granulocytic cell disorder could not be excluded. The plasma cell series was normal. A repeat test was refused.
The following investigations were normal or negative: blood urea, urinalysis, liver function tests, serum proteins and electrophoresis, Bence-Jones proteins, cryoglobulins, serum immunoglobulins, and complement; antibodies to nuclear, smooth muscle, gastric, thyroid and mitochondrial determinants; thyroid function tests, fasting blood sugar, chest and skeletal X-rays.
Comment
This patient's serum lipids are known to have remained normal since one year before developing generalized plane xanthoma (GPX) . Xanthoma presenting in this way initially suggested the possibility of primary biliary cirrhosis but this has been excluded. In the absence of serum lipid abnormality, dysproteinwmia, and definite myeloproliferative disorder this case falls into the group of normolipidxmic GPX without associated disease.
Including this present case, 37 patients have been recorded in the literature under this title (Lynch & Winkelmann 1966 , Feiwel 1968 , Moschella 1970 , Slack & Borrie 1971 , Kodama et al. 1972 , Millard & Church 1973 . Atypical xanthomatous lesions, however, have been present in at least 4 of these patients; 2 of them developed leukemia, 1 myeloma and one had histiocytosis X.
Myelomatosis has occurred in hyper-and normo-lipidamic cases in a ratio of 2:1 while benign paraproteinemias, including cryoglobulinmmia and macroglobulinmmia, have been equally distributed. Leuklmia and the unassociated disease cases have been, exclusively seen with normolipidamia (Table 1) . The appearance of GPX is usually with xanthelasma palpebrarum, and spreading xanthomatous papules and plaques over the head, neck and upper trunk, in some cases with involvement of the extremities. The xanthomata may preor post-date the development of myel6matosis or dysproteinemia; in 2 cases spontaneous resolution has occurred, leaving anetoderma-like lesions.
Two theories concerning the development of GPX have been proposed. Lynch & Winkelmann suggested that secondary xanthomatization of a local histiocytic cell proliferation might be responsible. Feiwel considered that development of paraproteinmemia might interfere with lipoprotein metabolism leading to hyperlipoproteinmmia and xanthomatosis. Further evidence for this latter concept has been produced by Kodama et al., in whose patient GPX was associated with a cryoglobulin composed of a monoclonal IgG (antibody) complexed with alpha-I and beta lipoprotein (antigen); in this case, however, the lipids appear to have been abnormal. L B, womanaged 45 History: In 1967 at menopause she noted hard lumps in both thighs, and again in 1969 around both knees, associated with aching and pain on kneeling. In the same year she passed a stone from the right kidney. In 1972 she developed lumps around both elbows and these discharged white chalky material. There is no muscle weakness and no history of Raynaud's phenomenon.
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On examination: Erythema of cheeks and forehead, purple indurated areas in both upper arms, hard plaques around knees, elbows and in thighs. Small papules over the extensor surfaces of both hands.
Investigations: Dietary assessment for the period 1968-71 showed a daily intake of 2500 calories, Histopathology: Nodule: epidermis slightly thickened; hyperkeratosis; in one area in the superficial dermis there is a defect in the collagen but no evidence of calcinosis. Area on upper arm: some condensation of collagen and loss of the skin appendages; appearances compatible with scleroderma (Fig 2) .
Discussion
In the absence of metabolic disease, causes of socalled dystrophic calcification include systemic lupus erythematosus, dermatomyositis and systemic sclerosis.
Dermatomyositis is worth considering in this case in view of two raised creatinine phosphokinase (CPK) levels; however, in this patient they have not been raised on all occasions. Creatinine phosphokinase levels are sensitive indicators of muscle damage and it is recognized that intramuscular injections can cause elevations in them. It may be that deposition of calcium is a cause and not an effect of muscle damage. Clinically there is no evidence of active muscle disease. Dystrophic calcification usually appears in association with other evidence of dermatomyositis such as muscle weakness, raised enzymes and sedimentation rate. It also appears after the disease has been in progress for two or more years.
Calcinosis cutis is seen in severe acrosclerosis as a late complication when the disease has been present for a decade or more. As evidence of longstanding disease it is associated with a more benign prognosis.
In many ways this woman resembles the 49year-old patient reported by Rabens & Bauer (1973) who had a history of nodules on all extremities with sclerodermatous lesions on the forehead, back of the neck and in both inguinal areas, appearing some three years later. This patient had an episode of congestive cardiac failure with atrial flutter and a 2:1 block. A pericardial effusion was also present, suggesting internal involvement. The mechanism of deposition of hydroxyapatite in damaged tissue is unknown but may be related to local changes in pH.
As adequate therapy for the tissue damage in this condition is at present unavailable, it is worth attempting to dissolve the ectopic calcification and to inhibit further deposition of hydroxyapatite. There is a close relationship between the calcium phosphorus product in the plasma and the tendency for ectopic calcification to occur. In one patient probenecid has been used to dissolve ectopic calcification (Dent & Stamp 1972) but in 4 subsequent patients no dissolution occurred. Aluminium hydroxide gel (Aludrox) has also been tried in treatment of ectopic calcification (Nassim & Connolly 1970 , Mozaffarian et al. 1972 ; this compound binds phosphate in the gut and may, if sufficient quantities are taken, produce osteomalacia (Dent & Winter 1974) .
Our patient was given Aludrox 30 ml four times daily with main meals (approximately 6.3 g AI(OH)3 per day). Urinary calcium and phosphorus excretion was monitored. Urinary phosphorus showed a significant but inadequate fall from 930 to 320 mg/24 hours. Urinary calcium rose from 180 to 200 mg/24 hours (Fig 3) . Reassessment of the patient's diet after one week showed that food taken between meals contained approximately 200 mg phosphorus per day. This was not taken with the aluminium hydroxide and therefore constituted a source of absorbable phosphorus. The 'between meal phosphorus' was stopped and there followed a satisfactory fall in urinary phosphorus to 20-50 mg/24 hours; urinary calcium rose to 230 mg/24 hours (see graph). Throughout this period plasma calcium, phosphorus and alkaline phosphatase remained unchanged; 24-hour urinary total hydroxyproline excretion also remained steady at 32 mg. It has been shown that it is unnecessary to lower plasma phosphorus appreciably when dissolving ectopic calcification in this way (Mozaffarian et al. 1972) .
It is as yet too early to assess the efficacy of this treatment. Further follow up with repeat X-rays will be required. We stress the need for monitoring the 24 hour urine for its phosphorus content which must be kept below 100 mg for the treatment to have a chance of succeeding., Dr F A Ive: In 1969 a number of cases of a condition known as tumoral calcinosis were reported from East Africa (Chater 1969 , Cooke 1969 . In this disease calcified nodules occurred in periarticular areas in the absence of overt connective tissue disease. Rather unusual lesions similar to those seen in this present case were described in 1970 by Whiting et al. I have one English boy with this disease under my care and a number of other cases in the United Kingdom have been recorded by Slavin et al. (1973) . I feel that a biopsy of a periarticular calcified area would be helpful in providing a more precise diagnosis.
